Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C

Dbouk, Nader; Arguedas, Miguel R.; Sheikh, Aasim

doi:10.1007/s10620-007-9985-z

Cited by 34 publications

(27 citation statements)

References 32 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An earlier study assessed the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C, comparing performance against 2 other screening questionnaires-the Center for Epidemiologic Studies Depression Scale and the BDI. 17 It found a strong correlation between the BDI and the PHQ-9, consistent with our results. Patients currently on interferon were included in the sample, which may have LR À indicates the negative likelihood ratio is the false negative rate divided by the true negative rate; LR+, the positive likelihood ratio is the true positive rate divided by the false positive rate and can be used to find the posttest odds, using formula: posttest odds=pretest odds ÂLR+; MINI, Mini International Neuropsychiatric Interview; PHQ-9, Patient Health Questionnaire-9.…”

Section: Discussionsupporting

confidence: 91%

“…In this study, researchers were not able to validate the PHQ-9 as a gold standard was not used. 17 Another study found moderate agreement between the BDI and the MINI in patients with chronic kidney disease, 18 also consistent with our results. The discrepancies between the BDI and the MINI may be because of selfreport of depressive symptoms versus clinical depression.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C

Scott

Wang

Coppel

et al. 2011

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 89%

Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C

Scott

Wang

Coppel

et al. 2011

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…The PHQ-9 has been shown to be a reliable and valid measure of depression severity in primary care 7 and physically ill populations in secondary care. [10][11][12] The GAD-7 is a reliable and valid measure of anxiety in primary care, 8 the general population 13 and secondary care. 14 The DLQI is widely used in dermatology for research purposes and has adequate validity and reliability.…”

Section: Procedurementioning

confidence: 99%

Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting

et al. 2016

View full text Add to dashboard Cite

Summary Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well‐being in people with psoriasis. Objectives To screen systematically for depression and anxiety in patients with psoriasis in routine clinical practice and to identify at‐risk groups for psychiatric morbidity. Methods Consecutive patients attending a single, tertiary centre over a 10‐month period were invited to complete the Patient Health Questionnaire Depression Scale (PHQ‐9), Generalized Anxiety Disorder Scale (GAD‐7) and Dermatology Life Quality Index (DLQI) as part of IMPARTS: Integrating Mental and Physical Healthcare: Research, Training and Services. Information on demographics, treatment and clinical disease severity was collated from electronic patient records. Regression models were used to identify at‐risk groups for psychiatric morbidity. Results Of 607 patients included (56·2% on biologics), 9·9% (95% confidence interval 7·5–12·3%) screened positive for major depressive disorder (MDD) and 13·1% (79/604) (95% confidence interval 10·4–15·8%) for generalized anxiety disorder (GAD; GAD‐7 score > 9). Suicidal ideation was reported in 35% of those with MDD; DLQI was < 10 in 38·3% and 45·6% cases of MDD and GAD, respectively. After adjusting for covariates, the risk of MDD or GAD was significantly higher in women and those with severe clinical disease, psoriatic arthritis and previous depression/anxiety. The risk of GAD was significantly increased with Asian ethnicity and use of topical treatments only. Conclusions Systematic screening for anxiety and depression identifies clinically important levels of depression and anxiety that may be missed using DLQI data alone. Women and those with severe disease, psoriatic arthritis and/or a prior history of psychiatric morbidity may be at particular risk.

show abstract

“…a group in another English-speaking country, one with a specific illness or one based in primary care). 85,[94][95][96][97] No such field testing had yet been carried out with the BSL population. Furthermore, the analysis of a large data set of patients who had used BSL-IAPT in terms of referral rates, adherence and clinical outcomes would enable calculation of recruitment targets should a full trial be indicated.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the effectiveness and cost-effectiveness of British Sign Language Improving Access to Psychological Therapies: an exploratory study

Young

Rogers

Davies

et al. 2017

Health Serv Deliv Res

View full text Add to dashboard Cite

BackgroundImproving Access to Psychological Therapies (IAPT) is a National Institute for Health and Care Excellence-approved approach to intervention for depression and/or anxiety. This exploratory study sets the groundwork for comparing psychological therapies for Deaf sign language users experiencing anxiety and/or depression, delivered in British Sign Language (BSL) by a Deaf therapist with usual access through an interpreter within the IAPT national programme.Objectives(1) To explore the following questions: (a) is BSL-IAPT more effective than standard IAPT for Deaf people with anxiety and/or depression? and (b) is any additional benefit from BSL-IAPT worth any additional cost to provide it? (2) To establish relevant BSL versions of assessment tools and methods to answer research questions (a) and (b). (3) To gauge the feasibility of a larger-scale definitive study and to inform its future design.DesignA mixed-methods exploratory study combing an economic model to synthesise data from multiple sources; a qualitative study of understanding and acceptability of randomisation and trial terminology; statistical determination of clinical cut-off points of standardised assessments in BSL; secondary data analysis of anonymised IAPT client records; realist inquiry incorporating interviews with service providers and survey results.SettingsIAPT service providers (NHS and private); the Deaf community.ParticipantsDeaf people who use BSL and who are clients of IAPT services (n = 502); healthy Deaf volunteers (n = 104); IAPT service providers (NHS and private) (n = 118).InterventionsIAPT at steps 2 and 3.Main outcome measuresReliable recovery and reliable improvement defined by IAPT; Deaf community views on the acceptability of randomisation; BSL terminology for trial-related language; clinical cut-off measurements for the BSL versions of the Patient Health Questionnaire-9 items (PHQ-9) and the Generalised Anxiety Disorder-7 (GAD-7); a valid BSL version of the EuroQol-5 Dimensions five-level version (EQ-5D-5L); costs, quality-adjusted life-years and incremental cost-effectiveness ratios.Data sourcesIAPT service provider anonymised records of the characteristics and clinical outcomes of Deaf BSL users of BSL-IAPT and of standard IAPT; published literature.ResultsRandomisation may be acceptable to Deaf people who use IAPT if linguistic and cultural requirements are addressed. Specifications for effective information in BSL for recruitment have been established. A valid EQ-5D-5L in BSL has been produced. The clinical cut-off point for the GAD-7 BSL is 6 and for the PHQ-9 BSL is 8. No significant difference in rates of reliable recovery and reliable improvement between Deaf users of standard IAPT or BSL-IAPT has been found. Whether or not BSL-IAPT is more cost-effective than standard IAPT is uncertain.LimitationsThe small number of participating standard IAPT services who have seen Deaf clients means that there is statistical uncertainty in the comparable clinical outcome result. Clinical cut-off scores have not been verified through gold standard clinical interview methodology. Limited data availability means that whether or not BSL-IAPT is more cost-effective than standard IAPT is uncertain.ConclusionsThere is a lack of evidence to definitively compare reliable recovery and reliable improvement between Deaf users of standard IAPT and BSL-IAPT. Instrumentation and prerequisites for a larger-scale study have been established.Future workA prospective observational study for definitive results is justified.FundingThe National Institute for Health Research Health Services and Delivery Research programme.

show abstract

Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C

Cited by 34 publications

References 32 publications

Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C

Diagnosis of Depression in Former Injection Drug Users With Chronic Hepatitis C

Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting

Evaluating the effectiveness and cost-effectiveness of British Sign Language Improving Access to Psychological Therapies: an exploratory study

Contact Info

Product

Resources

About